CR20250023A - SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3pGlu Aß Y USOS DE ESTAS - Google Patents

SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3pGlu Aß Y USOS DE ESTAS

Info

Publication number
CR20250023A
CR20250023A CR20250023A CR20250023A CR20250023A CR 20250023 A CR20250023 A CR 20250023A CR 20250023 A CR20250023 A CR 20250023A CR 20250023 A CR20250023 A CR 20250023A CR 20250023 A CR20250023 A CR 20250023A
Authority
CR
Costa Rica
Prior art keywords
n3pglu
antibodies
pharmaceutical solutions
pharmaceutical
solutions
Prior art date
Application number
CR20250023A
Other languages
English (en)
Inventor
John Corvari Vincent
Navanithan Sharma Anant
H Durbin Nicole
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20250023A publication Critical patent/CR20250023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se relaciona con soluciones farmacéuticas de ciertos anticuerpos anti-N3pGlu Aß. También se describen usos de tales soluciones farmacéuticas, que incluyen el uso en el tratamiento de la enfermedad de Alzheimer.
CR20250023A 2022-07-21 2023-07-20 SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3pGlu Aß Y USOS DE ESTAS CR20250023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369033P 2022-07-21 2022-07-21
PCT/US2023/070540 WO2024020470A1 (en) 2022-07-21 2023-07-20 PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CR20250023A true CR20250023A (es) 2025-02-17

Family

ID=87576063

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250023A CR20250023A (es) 2022-07-21 2023-07-20 SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3pGlu Aß Y USOS DE ESTAS

Country Status (18)

Country Link
EP (1) EP4558166A1 (es)
JP (1) JP2025525587A (es)
KR (1) KR20250037554A (es)
CN (1) CN119604302A (es)
AR (1) AR129994A1 (es)
AU (1) AU2023309007A1 (es)
CA (1) CA3261418A1 (es)
CL (1) CL2025000145A1 (es)
CO (1) CO2025000508A2 (es)
CR (1) CR20250023A (es)
DO (1) DOP2025000005A (es)
IL (1) IL318102A (es)
JO (1) JOP20250013A1 (es)
MA (1) MA71558A (es)
MX (1) MX2025000820A (es)
PE (1) PE20250785A1 (es)
TW (1) TW202421188A (es)
WO (1) WO2024020470A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

Also Published As

Publication number Publication date
PE20250785A1 (es) 2025-03-14
DOP2025000005A (es) 2025-02-28
CO2025000508A2 (es) 2025-02-04
WO2024020470A1 (en) 2024-01-25
JP2025525587A (ja) 2025-08-05
JOP20250013A1 (ar) 2025-01-21
CA3261418A1 (en) 2024-01-25
AU2023309007A1 (en) 2025-01-30
AR129994A1 (es) 2024-10-23
CN119604302A (zh) 2025-03-11
MA71558A (fr) 2025-05-30
TW202421188A (zh) 2024-06-01
MX2025000820A (es) 2025-03-07
IL318102A (en) 2025-02-01
KR20250037554A (ko) 2025-03-17
EP4558166A1 (en) 2025-05-28
CL2025000145A1 (es) 2025-05-30

Similar Documents

Publication Publication Date Title
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
BR0209777A (pt) Formulações lìquidas estáveis
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
JOP20190155B1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
GT200900268A (es) Polipeptidos de factor vii modificados y usos de los mismos .
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
TR199801722T2 (xx) Peptit imm�nojenler.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
CL2003002043A1 (es) Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card
AR029619A1 (es) Vacuna
BR112023023463A2 (pt) Inibidores da interação menin-mll
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
EP4566629A3 (en) Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
AR121118A1 (es) Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
BR112021014566A2 (pt) Moduladores de gpr35
CO2021011057A2 (es) Composición cosmética/dermatológica
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
MX2025000820A (es) SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTAS
MX2016005321A (es) Glicoproteinas recombinantes y sus usos.
JOP20250172A1 (ar) مُقترنات الأدوية والأجسام المضادة لـ cd70
BR112021016795A8 (pt) Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint